Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Almeida

Showing results (71-80 of 131) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology in Drug Development|May 11, 2016
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson DiseaseJosé-Francisco Rocha, Joaquim J Ferreira, Amílcar Falcão, et al.
The Journal of Cell Biology|September 20, 2018
Occluding junctions as novel regulators of tissue mechanics during wound repairLara Carvalho, Pedro Patricio, Susana Ponte, et al.
Current Medical Research and Opinion|April 10, 2010
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjectsTeresa Nunes, Eric Sicard, Luis Almeida, et al.
Lung India : Official Organ of Indian Chest Society|July 14, 2021
Clinical impact of obesity on respiratory diseases: A real-life studyArturo Cortes-Telles, Diana Lizbeth Ortiz-Farias, Yuri NoemI Pou-Aguilar, et al.
CNS Neuroscience & Therapeutics|July 27, 2010
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's diseaseJoaquim J Ferreira, Olivier Rascol, Werner Poewe, et al.
British Journal of Clinical Pharmacology|October 31, 2013
Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitorAna I Loureiro, Jose F Rocha, Carlos Fernandes-Lopes, et al.
Drugs in R&D|July 5, 2005
Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)Joana Maia, Manuel Vaz-da-Silva, Luis Almeida, et al.
Drugs in R&D|September 1, 2005
Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulationsCarlos Fontes-Ribeiro, Teresa Nunes, Amilcar Falcão, et al.
Epilepsia|July 29, 2010
Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsyPeter Halász, Joyce A Cramer, Danilo Hodoba, et al.
Epilepsy & Behavior : E&B|August 17, 2010
Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteersDenise Milovan, Luis Almeida, Myroslava K Romach, et al.
Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology in Drug Development|May 11, 2016
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson DiseaseJosé-Francisco Rocha, Joaquim J Ferreira, Amílcar Falcão, et al.
The Journal of Cell Biology|September 20, 2018
Occluding junctions as novel regulators of tissue mechanics during wound repairLara Carvalho, Pedro Patricio, Susana Ponte, et al.
Current Medical Research and Opinion|April 10, 2010
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjectsTeresa Nunes, Eric Sicard, Luis Almeida, et al.
Lung India : Official Organ of Indian Chest Society|July 14, 2021
Clinical impact of obesity on respiratory diseases: A real-life studyArturo Cortes-Telles, Diana Lizbeth Ortiz-Farias, Yuri NoemI Pou-Aguilar, et al.
CNS Neuroscience & Therapeutics|July 27, 2010
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's diseaseJoaquim J Ferreira, Olivier Rascol, Werner Poewe, et al.
British Journal of Clinical Pharmacology|October 31, 2013
Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitorAna I Loureiro, Jose F Rocha, Carlos Fernandes-Lopes, et al.
Drugs in R&D|July 5, 2005
Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)Joana Maia, Manuel Vaz-da-Silva, Luis Almeida, et al.
Drugs in R&D|September 1, 2005
Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulationsCarlos Fontes-Ribeiro, Teresa Nunes, Amilcar Falcão, et al.
Epilepsia|July 29, 2010
Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsyPeter Halász, Joyce A Cramer, Danilo Hodoba, et al.
Epilepsy & Behavior : E&B|August 17, 2010
Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteersDenise Milovan, Luis Almeida, Myroslava K Romach, et al.
Pageof 14